Related Experiment Video

Updated: Jun 30, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K

Darolutamide does not interfere with OATP-mediated uptake of docetaxel

Stefan A J Buck1, Zahra Talebi2, Thomas Drabison2

  • 1Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Centre Rotterdam, Rotterdam, The Netherlands.

International Journal of Cancer
|March 16, 2024
PubMed

Insights

Darolutamide, used with docetaxel for prostate cancer, does not affect docetaxel levels in patients. This study found no drug-drug interaction via OATP1B3 transporter, supporting combined therapy for metastatic prostate cancer.

Area of Science:

  • Pharmacology
  • Oncology
  • Drug Interactions

Background:

  • Metastatic prostate cancer treatment often involves docetaxel.
  • Darolutamide is an androgen receptor inhibitor approved for metastatic prostate cancer, often combined with docetaxel.
  • OATP1B3 transporter facilitates docetaxel uptake in prostate tumors and is inhibited by darolutamide in vitro.

Purpose of the Study:

  • To investigate the in vivo impact of darolutamide on docetaxel pharmacokinetics.
  • To assess potential drug-drug interactions mediated by OATP1B3 transporter inhibition.

Main Methods:

  • In vitro assays to determine OATP1B3 inhibition by darolutamide.
  • In vivo studies using patient-derived xenograft (PDX) models to assess docetaxel tumor accumulation.
  • Biomarker analysis in metastatic prostate cancer patients treated with darolutamide.

Main Results:

  • Darolutamide inhibited OATP1B3 in vitro at concentrations above Cmax.
  • In vivo, darolutamide did not alter the pharmacokinetics of Oatp1b substrates, including docetaxel.
  • Docetaxel tumor accumulation and OATP1B biomarker levels remained unchanged in the presence of darolutamide.

Conclusions:

  • Darolutamide does not significantly inhibit OATP1B3-mediated transport in vivo or in patients.
  • No OATP1B3 transporter-based drug-drug interaction was identified between darolutamide and docetaxel.
  • Combined therapy with docetaxel and darolutamide is supported for metastatic prostate cancer treatment.
Keywords:
OATPcabazitaxeldarolutamidedocetaxelprostate cancer

More Related Videos

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

7.6K
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

5.3K

Related Concept Videos

Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
80
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
2.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
200
Drug Elimination by Renal Route: Tubular Reabsorption01:22

Drug Elimination by Renal Route: Tubular Reabsorption

During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.4K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K